Citation Impact
Citing Papers
Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
2019
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
2012
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy
2020
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
2012
Regulation and Functions of the ER-Associated Nrf1 Transcription Factor
2022 StandoutNobel
Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation
2014 StandoutNobel
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
The single-cell transcriptional landscape of mammalian organogenesis
2019 StandoutNature
Guidance of regulatory T cell development by Satb1-dependent super-enhancer establishment
2016 StandoutNobel
PROTAC targeted protein degraders: the past is prologue
2022 Standout
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
2017
Coming of age: ten years of next-generation sequencing technologies
2016 Standout
The diverse roles of IRF4 in late germinal center B‐cell differentiation
2012
Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position
2013 Standout
Bone metastasis: the importance of the neighbourhood
2016
Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity
2024 StandoutNobel
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors
2015
Tissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment
2014 Standout
Comprehensive Integration of Single-Cell Data
2019 Standout
ATAC-see reveals the accessible genome by transposase-mediated imaging and sequencing
2016 StandoutNobel
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
2021
Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs
2014
Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway
2021 StandoutNobel
Organoid single-cell genomic atlas uncovers human-specific features of brain development
2019 StandoutNatureNobel
Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
2012
Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21
2015 StandoutNobel
Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway
2019
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
Resistance to proteasome inhibitors and other targeted therapies in myeloma
2018
Brazilian green propolis promotes TNFR2 expression on regulatory T cells
2021 StandoutNobel
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
2011
ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐Wide
2015 Standout
Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia
2021 StandoutNobel
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Impact of interferon-γ on hematopoiesis
2014
Lenalidomide efficacy in activated B ‐cell‐like subtype diffuse large B ‐cell lymphoma is dependent upon IRF 4 and cereblon expression
2012
Works of Arnold Bolomsky being referenced
Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response
2011
Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma
2016
Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro
2014
Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth
2012
High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone
2011
High expression of cereblon (CRBN ) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
2013